TY - JOUR
T1 - Epigallocatechin-3-Gallate Is Absorbed but Extensively Glucuronidated Following Oral Administration to Mice
AU - Lambert, Joshua D.
AU - Lee, Mao Jung
AU - Lu, Hong
AU - Meng, Xiaofeng
AU - Hong, Jihyeung Ju Jungil
AU - Seril, Darren N.
AU - Sturgill, Marc G.
AU - Yang, Chung S.
PY - 2003/12
Y1 - 2003/12
N2 - Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (Camellia sinensis), has shown cancer preventive activity in animal models. The bioavailability of EGCG in the most commonly used animal species, mice, is poorly understood. Moreover, the pharmacokinetic parameters of EGCG have not been reported previously in mice. Here we report that after administration of EGCG intravenously at 21.8 μmol/kg or intragastrically at 163.8 μmol/kg, the peak plasma levels of EGCG in male CF-1 mice were 2.7 ± 0.7 and 0.28 ± 0.08 μmol/L, respectively. EGCG was present mainly (50-90%) as the glucuronide. The plasma bioavailability of EGCG after intragastric administration was higher than previously reported in rats (26.5 ± 7.5% vs. 1.6 ± 0.6%). The conjugated EGCG displayed a shorter t1/2 (82.8-211.5 vs 804.9-1102.3 min) than unconjugated EGCG (P < 0.01, Student's t test). EGCG was present in the unconjugated form in the lung, prostate and other tissues at levels of 0.31-3.56 nmol/g after intravenous administration. Although intragastric administration resulted in lower levels in most tissues compared with intravenous administration (e.g., 0.006 ± 0.004 vs. 2.66 ± 1.0 nmol/g in the lung), the levels in the small intestine and colon were high at 45.2 ± 13.5 and 7.86 ± 2.4 nmol/g, respectively. This is the first report of the pharmacokinetic parameters of EGCG in mice. Such information provides a basis for understanding the bioavailability of EGCG in mice and should aid in understanding the cancer preventive activity of EGCG.
AB - Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (Camellia sinensis), has shown cancer preventive activity in animal models. The bioavailability of EGCG in the most commonly used animal species, mice, is poorly understood. Moreover, the pharmacokinetic parameters of EGCG have not been reported previously in mice. Here we report that after administration of EGCG intravenously at 21.8 μmol/kg or intragastrically at 163.8 μmol/kg, the peak plasma levels of EGCG in male CF-1 mice were 2.7 ± 0.7 and 0.28 ± 0.08 μmol/L, respectively. EGCG was present mainly (50-90%) as the glucuronide. The plasma bioavailability of EGCG after intragastric administration was higher than previously reported in rats (26.5 ± 7.5% vs. 1.6 ± 0.6%). The conjugated EGCG displayed a shorter t1/2 (82.8-211.5 vs 804.9-1102.3 min) than unconjugated EGCG (P < 0.01, Student's t test). EGCG was present in the unconjugated form in the lung, prostate and other tissues at levels of 0.31-3.56 nmol/g after intravenous administration. Although intragastric administration resulted in lower levels in most tissues compared with intravenous administration (e.g., 0.006 ± 0.004 vs. 2.66 ± 1.0 nmol/g in the lung), the levels in the small intestine and colon were high at 45.2 ± 13.5 and 7.86 ± 2.4 nmol/g, respectively. This is the first report of the pharmacokinetic parameters of EGCG in mice. Such information provides a basis for understanding the bioavailability of EGCG in mice and should aid in understanding the cancer preventive activity of EGCG.
UR - http://www.scopus.com/inward/record.url?scp=0345168968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345168968&partnerID=8YFLogxK
U2 - 10.1093/jn/133.12.4172
DO - 10.1093/jn/133.12.4172
M3 - Article
C2 - 14652367
AN - SCOPUS:0345168968
SN - 0022-3166
VL - 133
SP - 4172
EP - 4177
JO - Journal of Nutrition
JF - Journal of Nutrition
IS - 12
ER -